Seminal citrate is superior to PSA for detecting clinically significant prostate cancer

Seminal citrate is superior to PSA for detecting clinically significant prostate cancer

ABSTRACT Purpose: To establish whether the citrate concentration in the seminal fluid ([CITRATE]) measured by means of high-resolution nuclear magnetic resonance spectroscopy (1HNMRS) is superior to the serum prostate-specific antigen (PSA) concentration in detecting of clinically significant prost...

Full description

Bibliographic Details
Main Authors:	Emerson Pereira Gregório, Antonio Paulo Alexandrino, Ivania Terezinha Albrecht Schuquel, Willian Ferreira da Costa, Marco Aurelio de Freitas Rodrigues
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Urologia 2019-12-01
Series:	International Brazilian Journal of Urology
Subjects:	Prostate-Specific Antigen Prostate cancer familial [Supplementary Concept] Citrates
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000601113&tlng=en

Similar Items

Evaluation of PCA3 and multiparametric MRI’s: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL
by: Sezgin Okcelik, et al.
Published: (2016-06-01)

Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/ml
by: Emerson P. Gregorio, et al.
Published: (2007-04-01)

Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis
by: Zhiqiang Qin, et al.
Published: (2020-07-01)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

Prostate cancer in renal transplant recipients
by: Benjamin A. Sherer, et al.

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
by: Naseruddin Höti, et al.
Published: (2023-02-01)

Prostate Specific Antigen (PSA): The Historical Perspective
by: T. Ming Chu
Published: (2020-12-01)

PCA3 rs544190G>A and prostate cancer risk in an eastern Chinese population
by: Dalong Cao, et al.

Metastatic prostate cancer in the modern era of PSA screening
by: Philip A. Fontenot Jr, et al.

Incidence of histological prostatitis and its correlation with PSA density
by: Affonso Celso Piovesan, et al.
Published: (2009-11-01)

Predictors of Clinically Significant Prostate Cancer: A Comparative Study of PSA, PSA Density, and MRI Parameters
by: Mehmet Coşkun, et al.
Published: (2021-02-01)

Free PSA and prostate volume on the diagnosis of prostate carcinoma
by: Antonio Carlos Pereira Martins, et al.
Published: (2003-01-01)

Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values
by: Hasan Yilmaz, et al.
Published: (2015-06-01)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml−1
by: Ma-Ping Huang, et al.
Published: (2023-01-01)

AGE, TOTAL PSA, PSA DENSITY AND GLEASON SCORE, TAUS AS PREDICTIVE FACTORS IN PATIENTS WITH PROSTATE CANCER
by: Daruqutni Albar, et al.
Published: (2016-03-01)

Relationship of Prostate-Specific Antigen (PSA) and Prostate Volume in Patients with Biopsy Proven Benign Prostatic Hyperplasia (BPH)
by: Aulia Nur Fadila, et al.
Published: (2020-07-01)

Association of Connexin 32 with Prostate Volume and PSA Level in Prostatic Adenocarcinoma and Adenomyomatous Hyperplasia
by: Havva Erdem, et al.
Published: (2020-06-01)

THE CORRELATION BETWEEN SERUM PSA LEVEL AND PROSTATE HISTOLOGIC AGGRESSIVENESS WITH PROSTATIC VOLUME IN BPH PATIENTS
by: Gede Wirya Kusuma Duarsa, et al.
Published: (2019-01-01)

Effect of Finasteride on PSA and Histopathological Results in Patients Undergoing Prostate Biopsy
by: Saman Farshid, et al.
Published: (2022-12-01)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1
by: Lincoln GL Tan, et al.
Published: (2017-01-01)

Endourology and Benign Prostatic Hyperplasia in COVID-19 Pandemic
by: Alexis M. Alva Pinto, et al.
Published: (2020-07-01)

Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?
by: Jin-Woo Jung, et al.
Published: (2019-01-01)

Digital rectal examination (DRE) does not influence total serum levels of prostate specific antigen (tPSA), in individuals without prostate pathology
by: Maria de F. Figueirêdo, et al.
Published: (2003-10-01)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml-1
by: Cheng Wang, et al.
Published: (2021-01-01)

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range
by: I. Vukovic, et al.

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
by: Monica Vidal, et al.

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
by: Hyungseok Cho, et al.
Published: (2022-03-01)

Association between gleason score, psa level, PSAD and prostate volume, in a series of patients with prostate adenocarcinoma
by: Benedetti-Padrón Inés, et al.
Published: (2012-06-01)

Aberrant Expression of Citrate Synthase is Linked to Disease Progression and Clinical Outcome in Prostate Cancer
by: Cai Z, et al.
Published: (2020-07-01)

Active surveillance in intermediate risk prostate cancer: is it safe?
by: Nishanth Krishnananthan, et al.
Published: (2016-06-01)

Active surveillance in intermediate risk prostate cancer: is it safe?
by: Henk G. van der Poel, et al.
Published: (2016-06-01)

PSA density of the lesion: a mathematical formula that uses clinical and pathological data to predict biochemical recurrence in prostate cancer patients
by: PEDRO HENRIQUE REZENDE JUNQUEIRA, et al.
Published: (2021-10-01)

Serum PSA and cure perspective for prostate cancer in males with nonpalpable tumor
by: Marcos F. Dall'Oglio, et al.
Published: (2005-10-01)

Correlation Between Long-Term Acetylsalicylic Acid Use and Prostate Cancer Screening with PSA. Should We Reduce the PSA Cut-off for Patients in Chronic Therapy? A Multicenter Study
by: Mantica G, et al.
Published: (2022-10-01)

Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities
by: Fernando Maluf, et al.
Published: (2021-02-01)

Assessment of PSA-Age volume score in predicting positive prostate biopsy findings in Turkey
by: Oktay Uçer, et al.
Published: (2015-10-01)

Value of various PSA parameters for diagnosing prostate cancer in men with normal digital rectal examination
by: Ari Miotto Jr, et al.
Published: (2004-04-01)

Investigation of the relationship between endothelial nitric oxide synthase T786C polymorphism and PSA, PSA derivatives, and prostate cancer in the Turkish population
by: Balci Senay, et al.
Published: (2023-01-01)

Evaluation of PSA-age volume score in predicting prostate cancer in Chinese population
by: Yi-Shuo Wu, et al.
Published: (2018-01-01)

Survival of patients with prostate cancer and normal PSA levels treated by radical prostatectomy
by: Marcos F. Dall'oglio, et al.
Published: (2005-06-01)